June 26, 2021 : Issue #1144

TOP STORIES — Diabetes News and Research

Type 1 Diabetes and New Innovations

Long-Acting GLP-1 RAs compared to Short-Acting GLP-1 RAs

Increased Risk of Diabetic Retinopathy Due to Cataract Surgery

Last week, I was working with one of my interns and we were calculating some Carb and Correction Factors for bolus dosing of insulin. After Brenda Oppong, PharmD Candidate, LECOM School of Pharmacy, had that down we started practicing mealtime insulin use based on glucose readings and carbs, and taking into effect onboard insulin. She was doing all this on her iPhone on the calculator app. I mentioned how lucky she was, because when I first starting calculating doses, I had to do it on an old wire light calculator with no floating decimal or memory.

When she submitted her article for the week, I was reminded that not only have we come a long way with calculators and phones, we have made great progress since insulin was first used about 100 years ago. Check out her Laterpay feature on Type 1 Diabetes and New Innovations.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

A century after the discovery of insulin, new insulins, new devices, and other innovations may again change the future of treatment for type 1 diabetes.

How do the effectiveness and safety of long-acting GLP-1 RAs compare to short-acting GLP-1 RAs, when paired with basal insulin? 

Better management of diabetes and dyslipidemia could reduce cataract risk, and thus perhaps retinopathy risk as well.

Resistance training (RT) is an effective intervention for glycemic control and cardiometabolic health in individuals with type 2 diabetes (T2D). However, RT in individuals at risk for T2D to prevent or delay the onset of T2D, and RT program characteristics that are most effective, are still unknown. The purpose of this review is to determine the effects of RT on cardiometabolic risk factors in those at risk for T2D and to examine RT program characteristics associated with intervention effectiveness.

PubMed, Cochrane, Web of Science, and Embase databases were systematically searched for published controlled trials that compared cardiometabolic outcomes in adults with cardiometabolic risk for those that underwent an RT intervention with those that did not. A systematic review and meta-analysis were conducted to determine the effect of RT on glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), body fat percentage (BF%), total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides (TG). Additional analyses examined the effects of intervention duration and dietary intervention on FPG and TG. Fourteen trials with 668 participants were included.

The results concluded that RT is beneficial for improving glycemic control, BF%, and blood lipids in those at risk for diabetes. A dietary component did not result in more significant reductions in FPG and TG than RT alone. Resistance training (RT) effectively improves glycemic control and blood lipid profiles in adults at risk for type 2 diabetes (T2D). It could serve as an effective intervention to prevent or delay the onset of T2D. The researchers also concluded that free weight and resistance band training at intensities above 60% one-repetition maximum effectively improves glycemic control and blood lipid profiles in adults at risk for T2D.  Sports Medicine-Open

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:

Pierre Djemgou, PharmD Candidate Class of 2022, University of South Florida

Thi Vietthi Huynh, 2022 PharmD Candidate, Lake Erie College of Osteopathic Medicine – School of Pharmacy

Oluwatayo Ishola, PharmD. Candidate, South College, School of Pharmacy

Brenda Oppong, PharmD Candidate, LECOM School of Pharmacy 

Shadrielle Robbins, PharmD Candidate, South College School of Pharmacy

Olivia Shenouda, PharmD. Candidate, Florida A&M University School of Pharmacy

Your Friends in Diabetes Care
Steve and Dave

Diabetes In Control
www.diabetesincontrol.com